The main purpose of the treatment of persistent allergic rhinitis is to improve symptoms and
patients' quality of life and prevent the development of asthma. Therapeutic strategies also
target a reduction of pro-inflammatory mediators released from activated cells, including
mast cells and epithelial cells. The presence of allergic inflammation in nasal mucosa may
increase the risk of asthma occurrence, especially in patients with persistent allergic
rhinitis. H1 antihistamines are widely recommended in all types of allergic rhinitis,
regardless of symptom severity or persistence. They control all of the symptoms, but to a
lesser extent nasal congestion. New generation agents, such as levocetirizine and
desloratadine, possess anti-inflammatory properties, reducing allergic inflammation.
Phase:
Phase 4
Details
Lead Sponsor:
Iuliu Hatieganu University of Medicine and Pharmacy